Microbiological Best Laboratory Practices
Microbiological Best Laboratory Practices Get ready to download SOPs in PDF document
jvamsi6
Stop Letting AI Sign Your Name: FDA Warning on AI Use in Pharma GMP (2026)
Stop Letting AI Sign Your Name: Lessons from the Latest FDA Warning When we’re staring preparation of batch manufacturing record (BMRs) or any SOP the AI tool that can “draft” them in seconds. But the FDA just cleared its throat and the sound should make every Quality Head in the industry sit up a little straighter. The recent April 2026 warning letter regarding the “Inappropriate Use of AI” isn’t actually a strike against technology. It’s a strike against intellectual laziness. It’s Not About the Tool; It’s About the Authority The regulators didn’t walk into that facility and say,”Stop using AI.” They walked in and saw that the Quality Unit (QU) had checked out. The FDA observed AI-generated procedures and specifications being pushed through with reviews that were “not substantive enough. AI is incredibly good at looking right, even when it is fundamentally wrong. It can draft a sterility testing procedure that reads like a dream but misses a critical incubation nuance required by your specific product. 21 CFR 211.22(c) Is Not Negotiable: We often get bogged down in the “newness” of technology, but the regulations are remarkably old-school. 21 CFR 211.22(c) doesn’t care if a human, a robot, or a typewriter created the draft. It care about who owns the decision. If an auditor asks you to justify a sampling plan and your answer is, “The AI suggested it based on industry standards,” you’ve already lost the audit. A polished AI generated draft is not a defensible GMP decision. My Rule of Thumb for the Team: If we’re going to use AI in our workflow, we have to treat it like a brilliant but occasionally delusional assistant. Proofreading looks for typos. Verification looks for scientific integrity. We need to do the latter. When a QU person representative signs off on an AI-assisted document, they aren’t just saying “this looks okay.” They are saying, “I have verified this against cGMP and I am willing to defend it in a 483 response.” Conclusion: Innovation should make us faster, but it shouldn’t make us softer. Use AI to handle the tedious drafting, the formatting and the initial structuring. But when it comes to the actual judgment—the “is this safe for the patient?” part—keep your hands on the wheel. The FDA isn’t afraid of our computers. They’re afraid we’ve stopped using our brains. Let’s prove them wrong.
FDA 483 Observations 2025: Why Cleaning Validation Still Fails in Pharma GMP
FDA 483 Observations 2025: Why Cleaning Validation Still Fails in Pharma GMP When we talk about FDA observations in 2025, most people immediately think of complex microbiology issues—sterility failures, endotoxin results or media fill deviations. But the reality is quite different. The most common observation is still something basic: Cleaning and sanitization In 2025 alone, this was cited 95 times. That’s nearly 100 companies that believed their systems were clean—but the FDA found otherwise. It’s Not Just About Dirt This is not about a dirty floor or visible dust. For an FDA investigator, even a small residue on equipment is a warning sign. It reflects something deeper—a weak quality culture. A common issue seen in inspections is the “visual inspection gap.”Cleaning logs are filled and signed, but actual verification is weak. When inspectors find residues like “brownish deposits” inside valves or equipment parts, it clearly shows that checks are not effective. Cleaning Is a Scientific Process Many companies still treat cleaning as a routine or housekeeping activity. This is a serious mistake. Cleaning is not just about removing dirt—it is a validated process. The FDA is not asking only: “Is it clean?” They are asking: “Can you prove it is clean?” Key gaps observed: No proper disinfectant efficacy studies against facility isolates No defined clean hold time for equipment Poor or missing documentation In simple terms:If it is not documented, it did not happen. The CAPA Mistake: Only Retraining One common response to cleaning observations is retraining operators. But this approach is weak and overused. If the same issue appears across multiple companies, it is not just a human error—it is a quality system failure. A stronger CAPA approach should include: Equipment Improvement If surfaces are scratched, damaged, or pitted, proper cleaning is not possible. Repair, polish, or replace them. Clear and Specific SOPs Avoid vague instructions like “rinse thoroughly.”Instead, define exact steps: Quantity (e.g., 50 liters) Temperature (e.g., 80°C) Type of water (e.g., WFI) Visual Standards Operators should clearly understand what “clean” looks like.Use real images showing acceptable and unacceptable conditions. Conclusion: In 2025, FDA inspections are becoming more detailed. Inspectors are looking beyond visible cleanliness: Biofilms Residues in hard-to-reach areas Surface imperfections So don’t rely only on documentation. Walk through your facility with focus: Check under equipment Inspect valves and gaskets Look at hidden surfaces If you find something, don’t just clean it. Ask the real question: Why did this happen? Because true quality is not about cleaning once—it is about preventing it from happening again. 2025 statistics to the “Specifically” details and the necessary response strategy. Point of Failure Frequency (out of 95) What is the 483? (The Finding) Justification (FDA’s Reasoning) CAPA Proposal (The Fix) Cleaning Validation ~35 Failure to prove that the cleaning process works every time. If you haven’t validated the process, the drug is technically “adulterated.” CAPA: Conduct 3 consecutive successful “swab runs” to prove residue removal. Sanitization Efficacy ~25 Using a sanitizer that doesn’t kill the bacteria found in your facility. You are “sanitizing” with a chemical that is ineffective against your local microbes. CAPA: Perform Disinfectant Efficacy Testing (DET) using site-specific isolates. Equipment Design ~15 Scratched or “pitted” stainless steel surfaces. You cannot clean a surface that has microscopic holes or scratches where bacteria hide. CAPA: Polish/Electropolish the equipment or replace damaged parts. Hold Time Violations ~12 Leaving equipment dirty for too long (e.g., over the weekend). Long “Dirty Hold Times” lead to Biofilms, which are nearly impossible to clean. CAPA: Set strict “Hold Time” limits in the digital logbook with automatic alerts. Personnel Error ~8 Operators not following the written cleaning SOP. The best SOP in the world is useless if the human on the floor isn’t following it. CAPA: Strict “Training” To Personals about importance of cleaning and sanitization.
Decontamination, disposal of used media and used items.
DECONTAMINATION, DISPOSAL OF USED MEDIA AND USED ITEMS Get ready to download SOPs in PDF document
Operation, calibration and cleaning of different models of Balances.
Operation, calibration and cleaning of different models of Balances. STANDARD OPERATING PROCEDURE Pharma Micro Hub Title: OPERATION, CALIBRATION AND CLEANING OF BALANCES SOP Number: SOP/PMH/002-00 Department: MICROBIOLOGY Effective Date: 06/04/2026 Format Number: FMT/PM/002-05 Page Number: 1 of 19 1.0 OBJECTIVE 1.1 To lay down the procedure for operation, calibration and cleaning of different models of Balances. 2.0 SCOPE 2.1 This procedure is applicable for operation, calibration, and cleaning of different models of Balances located in the Microbiology Department of AET Laboratories Private Limited. 3.0 RESPONSIBILITIES 3.1 Microbiology analyst shall be responsible to follow the procedure as per the SOP. 3.2 Quality Control / Analytical Development personnel shall be responsible for the preventive maintenance activity. 4.0 ACCOUNTABILITY 4.1 Head/Designee – Microbiology. 5.0 PROCEDURE 5.1 Preliminary Check 5.1.1 Check and ensure the balance and its surrounding areas are clean and suitable for usage. 5.1.2 Use a soft brush for cleaning the pan and its surroundings and verify the calibration status. 5.1.3 Check the spirit level of the balance; if it is in the center, proceed for operation. If not in the center position, adjust it using the leveling feet. 5.1.4 Ensure that the total weight shall not exceed the minimum and maximum operating range of the balance. 5.1.5 Before weighing, bring the temperature of the material to be weighed to room temperature, if required. 5.1.6 Display the operation range of the balance with minimum and maximum weights (e.g., Range: 10g – 500g). 5.2 Cleaning 5.2.1 Ensure the power supply is switched ‘OFF’ before cleaning or preventive maintenance. 5.2.2 Clean the pan and inside of the balance with a lint-free cloth. 5.2.3 Use a soft brush for cleaning the pan and its surroundings. 5.2.4 Make an entry in the balance instrument usage logbook after cleaning. Cleaning activity shall be entered at the start and end of the shift. 5.2.5 Precautions must be taken to ensure no liquid enters the internal mechanism during cleaning. 5.3 Operating Procedure for Make: SARTORIUS | Model: SECURA 224-10IN 5.3.1 Ensure the cleanliness of equipment and platform; it should be clean and dry. 5.3.2 Check the spirit level; the bubble should be in the center of the circle. 5.3.3 Switch on the main power supply; the display shows “Secura”. 5.3.4 Slightly press the ON/OFF key and allow it to stabilize for 2-5 minutes. 5.3.5 When display shows “Leveling”, press the leveling icon. Ensure the bubble shows green. 5.3.6 Select the menu key on the bottom left of the weighing screen. 5.3.7 Menu Applications: 5.4 Sample Weighing 5.4.1 After calibration, press the Tare/Zero key. Wait for a stable zero reading. 5.4.2 Place the sample/container in the center of the pan. Close the draft shield window. 5.4.3 Wait for stabilization, then record the weight. Clean the balance after weighing. 5.4.4 Put the balance in standby mode when not in use. 5.5 Data Printer Operation 5.5.1 Connect the printer and switch on the power. Green light indicates readiness. 5.5.2 Press the “Print” button to generate the header (Date/Time). 5.7.1 Daily Calibration (Self-Calibration) 5.7.1.1 Perform self-calibration daily after 30 minutes of warm-up. 5.7.1.2 Select “CAL” from the menu and press “CAL-Intern”. 5.7.1.3 Verify weights: 0.1g, 1g, 10g, and 200g. Record in Annexure-01. 5.7.1.4 Acceptance Tolerance: Variation should not exceed ± 0.1% of certified value. 5.7.2 Monthly Calibration 5.7.2.1 Sensitivity: Place 200g weight. Limit: ± 0.05%. 5.7.2.2 Eccentricity: Place 100g weight in center and 4 corners. Limit: ± 0.05%. 5.7.2.3 Repeatability: 10 weighings of 200mg weight. Limit: ± 0.10% (Uncertainty). 5.7.2.4 Linearity: Test 100mg, 200mg, 500mg, 1g, 100g, 200g. Limit: ± 0.05%. 6.0 ABBREVIATIONS 8.0 ANNEXURES PHARMA MICROHUB ANNEXURE-01: ANALYTICAL BALANCE DAILY CALIBRATION RECORD SOP No:SOP/PH/002-00 Format No: FMT/PH/002-00 Effective Date: 06/04/2026 Page No: 01 of 01 DAILY CALIBRATION LOG Instrument Name/ID: ________________________ Month/Year: ________________ Date Standard Weight (g) Observed Weight (g) Deviation (%) Sign (Analyst) 0.1 g 1.0 g 10.0 g 200.0 g Next Date: 0.1 g 1.0 g 10.0 g 200.0 g Acceptance Criteria: For 0.1g to 200g the variation should not be more than ± 0.1% of the certified mass value. Prepared By (Analyst) Checked By (QA) PHARMA MICROHUB ANNEXURE-02: ANALYTICAL BALANCE MONTHLY CALIBRATION RECORD SOP No: SOP/PH/002-00 Format No: FMT/PH/002-00 1. SENSITIVITY (Std. Weight: 200g) Standard Weight: 200.0000g Observed Weight: __________ g Limit: ± 0.05% 2. ECCENTRICITY (Std. Weight: 100g) Position Observed (g) Deviation (%) Position Observed (g) Deviation (%) Center (1) — Front Left (2) Back Left (3) Back Right (4) Front Right (5) Limit: ± 0.05% 3. REPEATABILITY (Std. Weight: 200mg | n=10) 1. ______ 2. ______ 3. ______ 4. ______ 5. ______ 6. ______ 7. ______ 8. ______ 9. ______ 10. ______SD: _________ | Uncertainty ($U$): _________% (Limit: ± 0.10%) 4. LINEARITY (Limit: ± 0.05%) Weight 100 mg 200 mg 500 mg 1 g 100 g Observed Analyzed By Checked By (QA) Approved By (HOD) PHARMA MICROHUB ANNEXURE-03: CLEANING & OPERATION LOG SOP No: SOP/PH/002-00 Format No: FMT/PH/003-00 CLEANING AND OPERATION OF TOP LOAD BALANCE LOG Date Product/Material Name Batch No. / AR No. Cleaning Status (Start/End) Sign (Analyst) Note: Cleaning must be performed before and after each usage. Ensure spillage is cleaned immediately. Verified By (Supervisor/QA) Date of Review Get ready to download editable SOPs in word document
Logging, Investigating, reporting, and disposing of Microbiology Laboratory Incidents.
Logging, Investigating, reporting, and disposing of Microbiology Laboratory Incidents. Pharma Micro Hub Document No: SOP/MB/XXX TOPIC: Microbiology Lab Incident Procedure Revision Date: 05-Apr-2028 Effective Date: 06-Apr-2026 Supersedes: New Page No: 1 of 3 Approved By: Head QA 1.0 Objective To lay down a procedure for Logging, Investigating, reporting, and disposing of Microbiology Laboratory Incidents. 2.0 Scope This procedure is applicable for all the laboratory incidents logged in the Microbiology Laboratory. 3.0 Responsibility 4.0 Accountability Head/Designee – Microbiology. 5.0 Procedure 5.1 General Definitions 5.1.1 Incident: An incident can be defined as an unplanned or uncontrolled event in the form of non-compliance to the designed system or procedures at any stage during receipt, storage, handling, disposal and analysis of samples due to system failure, environmental variations, procedural errors or equipment breakdown or manual error. 5.2 Incident Types 5.4 Numbering of Laboratory Investigation Report (LIR) 5.4.11Numbering Format: LIR/PM/YY/XXX The unique identification number for an LIR is constructed as follows: Example: The first LIR filed in the Microbiology department for the year 2026 would be numbered as: LIR/PM/26/001 Laboratory supervisor is responsible for assigning the number for LIR in Annexure-01. Note: In the absence of the Laboratory supervisor, the analyst can initiate the LIR. 5.5 LIR Investigation, Closing and Disposition of Incidents 6.0 Abbreviations Abbreviation Full Form LIR Laboratory Investigation Report HOD Head of the Department QA Quality Assurance SOP Standard Operating Procedure 8.0 Annexures Get ready to download editable SOPs in word document
Media Shelf Life Validation Protocol | USP <61> & <62> Compliant.
Media Shelf Life Validation Protocol | USP & Compliant. PHARMA MICRO HUB VALIDATION PROTOCOL TITLE: SHELF LIFE DETERMINATION OF PREPARED MICROBIOLOGICAL MEDIA Protocol No: PMH/VP/001-00 Effective Date: April 2026 1.0 OBJECTIVE To define the detailed procedure for determining the shelf life of prepared microbiological media by evaluating pH stability, physical integrity, and growth promotion capability over a 14-day study period. 2.0 SCOPE This protocol is applicable to all dehydrated media lots prepared, sterilized, and stored at 22.5 ± 2.5°C within the Microbiology Laboratory of Pharma Micro Hub. 3.0 RESPONSIBILITY Designation Responsibility Microbiologist Execution of media preparation, sterilization, pH measurement, physical checks, and GPT. Head – Microbiology Technical review of raw data, calculation of recovery percentages, and report verification. Head – QA Final approval of the protocol and authorization of the established shelf life. 4.0 PRE-REQUISITES 5.0 PROCEDURE 5.1 Media Preparation: Reconstitute dehydrated media powder in purified water and mix properly. Sterilize at 121°C for 15 minutes at validated autoclave as per SOP. Cool to 45-50°C and pour 20-25ml into sterile plates aseptically under LAF. 5.2 Physical Check: Visually inspect the plates for colour change, excessive moisture, cracks or microbial contamination. 5.3 pH Procedure: Calibrate the pH meter using standard buffers then Measure pH of solidified agar and broth media at 25°C. Acceptable limit is ±0.2 or as per manufacture recomenadtions. 5.4 GPT Performance: Inoculate test organisms in media with 10-100 CFU of challenge organisms. Incubate per USP <61>/<62> and confirm recovery is 50-200% compared to fresh control media. 6.0 ANNEXURES Annexure I: Media Preparation & GPT Log.Annexure II: Physical & pH Observation Sheet. 7.0 REFERENCES 8.0 ABBREVIATIONS GPT: Growth Promotion Test LAF: Laminar Air Flow USP: United States Pharmacopeia CFU: Colony Forming Unit. PHARMA MICRO HUB VALIDATION SUMMARY REPORT Report No: PMH/VR/001-00 REF PROTOCOL NO: PMH/VP/001-00 Date: April 2026 1.0 OBJECTIVE To summarize and evaluate the analytical data obtained during the 14-day hold-time study to establish the final shelf life for prepared media. 2.0 SCOPE This report covers the stability evaluation of media batches stored under controlled laboratory conditions (22.5 ± 2.5°C). 3.0 RESPONSIBILITY Designation Responsibility Microbiology Team Compiling results from Day 0, Day 7, and Day 14 into the summary report. QA Department Reviewing summary against protocol and authorizing the final shelf life. 4.0 REQUISITES USED Qualified ATCC organisms, validated dehydrated media lots, and calibrated pH analysis systems. 5.0 PROCEDURE FOLLOWED The study was executed per Protocol PMH/VP/001-00. Testing for GPT, pH, and physical appearance was performed at Day 0, Day 7, and Day 14 intervals. 6.0 RESULTS SUMMARY Media Name Parameter Day 0 Day 7 Day 14 SCDA / SCDM pH & Appearance Pass Pass Pass SDA GPT Recovery Pass Pass Pass 7.0 CONCLUSION All prepared media batches met the acceptance criteria for pH stability, physical integrity, and growth promotion capability (50-200% recovery) throughout the 14-day study duration. 8.0 RECOMMENDATIONS The validated shelf life for prepared microbiological media is established as 10 days from sterilization date at 22.5 ± 2.5°c. ANNEXURES Annexure I: GPT Recovery Log Template Organism Control (CFU) Test (CFU) % Recovery Annexure II: pH & Physical Appearance Log Interval pH Observed Physical Appearance Day 0 / 7 / 14 Get ready to purchase editable validation in word document.
